EV Biologics, Inc. (YECO) Stock Price & Analysis
EV Biologics, Inc. (YECO) — price $0.0004 (0.00%), as of the Nov 18, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
EV Biologics, Inc. · YECO
Yulong Eco-Materials Limited, operating as EV Biologics, Inc., is a biotechnology firm headquartered in Cheyenne, US. The company specializes in developing extracellular vesicles (EVs) for diagnostics and therapeutics, alongside human mesenchymal and other stem cell-derived products for cosmetic and biopharmaceutical applications, leveraging its proprietary multifunctional EV platform.
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0004 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0001 – $0.1056 | |
| Shares traded on the day | 10.0K |
Price & events
Other perspectives
Council score for EV Biologics (YECO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is EV Biologics (YECO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. EV Biologics, Inc. (YECO) is the company analyzed here. It employs 284 people and is led by Daniel S. McKinney. In Q3 FY2025 it reported revenue of $9,000 and net income of -$48,290.
What do the latest results show for EV Biologics (YECO)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $9,000.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $9,000 | -$48,290 | -$0.0047 (diluted) |
| Q1 FY2025 | $48,000 | $4,709 | $0.0005 (diluted) |
| Q4 FY2024 | $40,344 | $7,510 | $0.0010 (diluted) |
What are the financial strengths and risks for EV Biologics (YECO)?
Short answer · as of
The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 3.11.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held YECO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported YECO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About YECO
These answers are editorial: 1 of these 1 answer is drawn from the YECO research dossier (written Jun 14, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What are the key growth opportunities for YECO in healthcare?
YECO's primary growth opportunities in healthcare stem from its innovative extracellular vesicle (EV) platform and its stem cell-derived products. One significant area is the advancement of EV-based therapeutics and vaccines.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com